GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » ROC %

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) ROC % : -226.01% (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. BioCryst Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2023 was -226.01%.

As of today (2024-04-29), BioCryst Pharmaceuticals's WACC % is 10.97%. BioCryst Pharmaceuticals's ROC % is -184.59% (calculated using TTM income statement data). BioCryst Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


BioCryst Pharmaceuticals ROC % Historical Data

The historical data trend for BioCryst Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals ROC % Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -152.63 -310.73 -342.18 -239.32 -113.02

BioCryst Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -291.13 -222.07 -278.13 -142.80 -226.01

BioCryst Pharmaceuticals ROC % Calculation

BioCryst Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-103.709 * ( 1 - -0.14% )/( (73.55 + 110.234)/ 2 )
=-103.8541926/91.892
=-113.02 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=516.96 - 60.748 - ( 388.987 - max(0, 149.988 - 495.966+388.987))
=110.234

BioCryst Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-170.68 * ( 1 - 2.27% )/( (37.375 + 110.234)/ 2 )
=-166.805564/73.8045
=-226.01 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=516.96 - 60.748 - ( 388.987 - max(0, 149.988 - 495.966+388.987))
=110.234

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCryst Pharmaceuticals  (NAS:BCRX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, BioCryst Pharmaceuticals's WACC % is 10.97%. BioCryst Pharmaceuticals's ROC % is -184.59% (calculated using TTM income statement data). BioCryst Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


BioCryst Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
George B Abercrombie director C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
William P Sheridan officer: SR VP - CMO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703

BioCryst Pharmaceuticals (BioCryst Pharmaceuticals) Headlines

From GuruFocus